For providers
STAT Breast Cancer Panel with the Riskguard® test

Faster genetic insights for informed surgical decisions

Introducing the new STAT Breast Cancer Panel as part of the Riskguard test. With expedited results from nine genes associated with breast cancer, healthcare providers and patients can make more informed surgical decisions, more quickly.
Four surgeons wearing caps and masks in an operating room, performing surgery.
Gauge cancer risk to inform surgical decisions, treatments, and risk-management options
Get results approximately 7-10 days from sample receipt
New York state approved
Covered by Medicare and many commercial insurance plans*
Four surgeons wearing caps and masks in an operating room, performing surgery.
A purple DNA double helix.

Nine life-changing gene results. Delivered when patients need them the most.

As an expedited subset of the full 59-gene Riskguard test, our STAT Breast Cancer Panel examines nine genes associated with an increased risk for hereditary breast cancer and provides the fast results necessary for treatment decisions.

ATM
BRCA1
BRCA2
CDH1
CHEK2
PALB2
PTEN
STK11
TP53

Fast turnaround time

Results for the STAT Breast Cancer Panel should be available approximately 7 to 10 days from sample receipt, with the comprehensive Riskguard results following 7 to 14 days later.

Informs clinical intervention

Timely genetic testing can help with difficult surgical and therapeutic decisions. If your patient is positive for a clinically-relevant variant in one of the nine high-risk genes on the STAT Breast Cancer Panel, they may choose to opt for a more invasive surgical intervention.

The 20-year risk of developing a contralateral breast cancer for a BRCA1 carrier is 30-40% and 25% for carriers of BRCA2.1

There is also contralateral breast cancer risk among carriers of other genes.1

Susan: A CHEK2 case study

A 50-year-old non-Hispanic White female diagnosed with breast cancer​ who wants more information before deciding on surgery

  • Tumor size:​ 2.5cm
  • Family history: A sister with breast cancer (age 62) and a grandmother with breast cancer (age 43​)
  • STAT Breast Cancer Panel results: Positive for CHEK2​
A woman looking straight ahead and smiling.
Not an actual patient
A woman standing in front of trees, looking slightly to the right.
Not an actual patient

Lily: A BRCA1 case study

A 36-year-old Black female with diabetes and recently diagnosed with invasive breast cancer

  • Tumor size: 2cm
  • Family history: Unknown
  • STAT Breast Cancer Panel results: Positive for BRCA1​

Streamlined ordering. From login to checkout.

  • Log in to the Exact Sciences Provider Hub and select the Riskguard test
  • Check the box for the STAT Breast Cancer Panel under the Clinical Information section
  • Submit your order
An Exact Sciences Provider Hub screen showing a checkbox to select the STAT Breast Cancer Panel when ordering the Riskguard test.

We're here for you

With questions about ordering the Riskguard test, insurance billing and payment options, checking results, or getting connected with a genetic counselor, call us at +1 866-662-6897 or email us at riskguard@exactsciences.com.
The Exact Sciences Riskguard test was developed, and its performance characteristics validated by an Exact Sciences laboratory following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. The test is performed in Marshfield, WI at PreventionGenetics LLC, a wholly owned subsidiary of Exact Sciences. PreventionGenetics is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing. It has not been cleared or approved by the US Food and Drug Administration or other notified regulatory authority. Genomic Health, Inc., an Exact Sciences company, is the billing entity for the Riskguard test.